- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06268769
Relación tacrolimus C:D medida en receptores de trasplante renal tratados con fármacos de liberación prolongada una vez al día (TaC:Drop)
Ensayo de superioridad multicéntrico, abierto, aleatorizado, de dos brazos, de grupos paralelos para evaluar la biodisponibilidad y viabilidad de dos formulaciones de tacrolimus una vez al día, Envarsus® en comparación con Advagraf ™, administradas en receptores de trasplantes de riñón
The goal of this clinical trial is to compare the bioavailability and practicability of two different formulations of tacrolimus in kidney transplant recipients. The main objective is to demonstrate that Envarsus® (test drug) has superior (higher) oral bioavailability compared with Advagraf™ (comparator drug) at 12 weeks after kidney transplantation. The trial also aims to compare the practicability (handling) of the two drugs using a series of pharmacokinetic parameters and to explore the relationship between drug bioavailability and long-term clinical outcomes, with a special focus on dose-dependent adverse reactions, measured until 3 years post-transplantation. The trial incorporates a pharmacokinetic sub-study designed to profile the peak tacrolimus blood concentration up to 6 hours after drug intake on the day of the 12-week study visit.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This clinical trial aims to compare the bioavailability and practicability of two alternative once-daily formulations of tacrolimus in patients who have received either a first or second kidney transplant and require prophylactic immunosuppressive treatment to prevent allograft rejection. Trial participants are randomised within 7 days prior to kidney transplantation surgery in a 1:1 ratio to two alternative treatment arms containing either Envarsus (test arm) or Advagraf (comparator arm) as first-line calcineurin inhibitor within a standard-of-care immunosuppressive regimen. Tacrolimus blood trough levels and drug doses are monitored at regular intervals to measure a dose-normalised trough level (concentration/dose, C/D ratio) as an estimate of tacrolimus bioavailability.
The primary objective is to demonstrate that the C/D ratio of tacrolimus measured in kidney transplant recipients treated with Envarsus® (test drug) is superior to (higher than) the C/D ratio measured in patients treated with Advagraf™ (comparator drug) at 12 weeks post-transplantation. The trial also aims to compare the practicability (handling) of these two once-daily drug formulations using a series of pharmacokinetic parameters that will measure the speed with which therapeutic blood trough levels are attained and the ease with which stable blood trough levels are maintained over time.
Secondarily, TaC:Drop aims to explore the relationship between the early C/D ratio measured at 12 weeks post-transplantation and later clinical outcomes measured until three years post-transplantation. The study aims to investigate whether a superior pharmacokinetic drug profile is associated with fewer and milder dose-dependent drug toxicities and superior kidney graft function, as measured by long-term safety and efficacy parameters.
Drug pharmacokinetics will be explored in greater detail during a sub-study designed to profile the peak blood concentration of Envarsus® and Advagraf™ at 12 weeks post-transplantation in patients who volunteer to provide three additional blood samples at two-hour intervals after drug intake on the day of the 12-week trial visit. Participation in this sub-study is voluntary and available to all trial centres and all trial patients.
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 4
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Aachen, Alemania, 52074
- University Hospital Aachen, Department of General, Visceral and Transplant Surgery
-
Berlin, Alemania, 10117
- Charité Universitätsmedizin, Department of Nephrology and Medical Intensive Care
-
Bochum, Alemania, 44892
- Knappschaft Clinic, University Hospital Bochum, Department of Surgery
-
Dresden, Alemania, 01307
- University Hospital Dresden, Division of Nephrology
-
Hamburg, Alemania, 20251
- University Medical Center Hamburg-Eppendorf, Internal Medicine III (Nephrology, Rheumatology, Endocrinology)
-
Hanover, Alemania, 30625
- Hannover Medical School, Department of General, Visceral and Transplant Surgery
-
Jena, Alemania, 07747
- University Hospital Jena, Internal Medicine III, Nephrology
-
Mainz, Alemania, 55131
- University Medical Center of the Johannes Gutenberg University Mainz, Medical Clinic I. (Nephrology)
-
Mannheim, Alemania, 68167
- University Hospital Mannheim, Medical Clinic V
-
Munich, Alemania, 81377
- LMU University Hospital Munich, Department of General, Visceral and Transplant Surgery
-
Münster, Alemania, 48149
- University Hospital Münster, Medical Clinic D
-
Regensburg, Alemania, 93053
- University Hospital Regensburg, Department of Nephrology
-
Würzburg, Alemania, 97080
- University Hospital Würzburg, Medical Clinic I, Department of Nephrology
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Signed and dated written informed consent
- Adult (≥18 years old) male or female
- Renal insufficiency necessitating kidney transplantation and approved to receive a first or second kidney allograft from a living or deceased organ donor
- ABO blood type compatible with the donor kidney
- Able to swallow an oral formulation of tacrolimus in tablet or capsule form
Exclusion Criteria:
- Multi-organ transplantation
- Any previous solid organ transplantation (other than a first kidney allograft)
- For recipients of a second kidney transplant: loss of first kidney transplant within 2 years after transplantation owing to immunological reasons or recurrence of the underlying renal disease
- Patient and/or donor is positive for active HCV, HBV or HIV infection
- History of any malignancy that could not be curatively treated
- Ongoing abuse of drugs or alcohol
- Signs of advanced liver disease or any signs of liver decompensation
- Ongoing uncontrolled systemic infection
- Severe diarrhoea, vomiting, active peptic ulcer, previous bariatric surgery, or any other gastrointestinal disorder that may affect absorption of tacrolimus
- Planned or foreseeable use of cyclosporine, belatacept or any tacrolimus preparation other than Envarsus® or Advagraf™
- Known contraindication or hypersensitivity to tacrolimus, and/or to any of the excipients listed in section 6.1 of the Summary of Product Characteristics (SmPC) of both Envarsus® and Advagraf™, and/or to any other macrolides
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test
- Women of child-bearing potential (WOCBP), defined as all women physiologically capable of becoming pregnant, unless using a highly-effective method of contraception
- Participation in another interventional clinical trial in the time period starting from 4 weeks prior to randomisation and throughout the entire trial period
- Any condition or factor which, in the judgement of the investigator, would place the subject at undue risk, invalidate communication with the investigator or study team, or hamper compliance with the trial protocol or follow-up schedule
- Inability to freely give informed consent (e.g. individuals under legal guardianship)
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Envarsus
Participants take prolonged-release tacrolimus tablets (Envarsus) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice. |
Envarsus tablets dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
Otros nombres:
|
|
Comparador activo: Advagraf
Participants take prolonged-release tacrolimus capsules (Advagraf) orally once daily and additionally receive standard-of-care immunosuppressive background therapy according to routine practice. |
Advagraf capsules dosed to achieve and maintain whole blood trough levels of tacrolimus within a therapeutic range of 5-12 ng/ml during the first 4 weeks post-transplantation, and 5-8 ng/ml thereafter.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Dose-normalised blood trough level of tacrolimus (concentration/dose ratio)
Periodo de tiempo: 12 weeks after kidney transplantation
|
To calculate C/D ratio, "concentration" is the blood trough level of tacrolimus measured in a blood sample collected immediately prior to drug dosing on the day of the 12-week trial visit and "dose" is the daily dose taken by the patient on the day prior to the visit. C/D ratio is measured as a surrogate for tacrolimus bioavailability (i.e. systemic exposure per mg of drug). The primary endpoint uses a blood trough level reading that is measured in a central laboratory. |
12 weeks after kidney transplantation
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Proporción de pacientes con niveles mínimos inferiores, dentro o superiores al rango objetivo
Periodo de tiempo: 4 días, 14 días, 28 días y 12 semanas después del trasplante de riñón
|
4 días, 14 días, 28 días y 12 semanas después del trasplante de riñón
|
|
|
Nivel mínimo medio de tacrolimus y variabilidad (rango) entre pacientes de los niveles mínimos de tacrolimus
Periodo de tiempo: 4 días, 14 días, 28 días y 12 semanas después del trasplante de riñón
|
4 días, 14 días, 28 días y 12 semanas después del trasplante de riñón
|
|
|
Dosis diaria media de tacrolimus y variabilidad (rango) entre pacientes de la dosis diaria de tacrolimus
Periodo de tiempo: 4 días, 14 días, 28 días y 12 semanas después del trasplante de riñón
|
4 días, 14 días, 28 días y 12 semanas después del trasplante de riñón
|
|
|
Variabilidad intrapaciente de la relación C/D y la dosis diaria
Periodo de tiempo: Medido en los puntos de tiempo: día 4, día 14, día 28 y semana 12
|
Medido en los puntos de tiempo: día 4, día 14, día 28 y semana 12
|
|
|
Tasa de incidencia de biopsias por causa
Periodo de tiempo: 12 semanas después del trasplante de riñón
|
12 semanas después del trasplante de riñón
|
|
|
Tasa de incidencia de episodios de rechazo agudo que requieren tratamiento
Periodo de tiempo: 12 semanas después del trasplante de riñón
|
12 semanas después del trasplante de riñón
|
|
|
Tasa de incidencia de episodios de rechazo agudo comprobado mediante biopsia resistentes a esteroides
Periodo de tiempo: 12 semanas y 1 año después del trasplante de riñón
|
12 semanas y 1 año después del trasplante de riñón
|
|
|
Incidencia de infección por CMV y BKV (incluida la manifestación en órganos, si corresponde)
Periodo de tiempo: 12 semanas y 1 año después del trasplante de riñón
|
12 semanas y 1 año después del trasplante de riñón
|
|
|
Incidencia, tipo, gravedad y gravedad de las reacciones adversas (RA)
Periodo de tiempo: 12 semanas y 3 años después del trasplante de riñón
|
12 semanas y 3 años después del trasplante de riñón
|
|
|
Presión arterial
Periodo de tiempo: 12 semanas y 1, 2, 3 años después del trasplante de riñón
|
12 semanas y 1, 2, 3 años después del trasplante de riñón
|
|
|
Incidencia de trastornos gastrointestinales que requieren investigación diagnóstica.
Periodo de tiempo: 12 semanas y 3 años después del trasplante de riñón
|
12 semanas y 3 años después del trasplante de riñón
|
|
|
Recurrencia de enfermedad renal primaria.
Periodo de tiempo: 12 semanas y 3 años después del trasplante de riñón
|
12 semanas y 3 años después del trasplante de riñón
|
|
|
Incidencia de ASD de novo
Periodo de tiempo: Detectado dentro del primer año después del trasplante de riñón.
|
Detectado dentro del primer año después del trasplante de riñón.
|
|
|
Dosis y duración del tratamiento con glucocorticosteroides.
Periodo de tiempo: 12 semanas y 1, 2, 3 años después del trasplante de riñón
|
12 semanas y 1, 2, 3 años después del trasplante de riñón
|
|
|
Incidencia y tiempo hasta estudiar la interrupción del tratamiento.
Periodo de tiempo: 3 años después del trasplante de riñón
|
3 años después del trasplante de riñón
|
|
|
Incidencia, tiempo y motivo de la retirada del paciente del estudio
Periodo de tiempo: 3 años después del trasplante de riñón
|
3 años después del trasplante de riñón
|
|
|
Time to reach the first trough level in target range
Periodo de tiempo: Time period measured in days, assessed within the first 2 weeks after kidney transplantation
|
Reaching the target range is defined as two consecutive readings within the initial target range of 5-12 ng/ml; time is measured to the date of the first in-range reading |
Time period measured in days, assessed within the first 2 weeks after kidney transplantation
|
|
Tacrolimus concentration/dose (C/D) ratio
Periodo de tiempo: 4 days, 14 days, 28 days and 1, 2, 3 years after kidney transplantation
|
The secondary endpoint using C/D ratio data takes a blood trough level reading that is measured in the local laboratory at the trial site. |
4 days, 14 days, 28 days and 1, 2, 3 years after kidney transplantation
|
|
Treatment failure rate
Periodo de tiempo: 12 weeks and 1, 2, 3 years after kidney transplantation
|
A composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or re-transplantation), or death (from any cause) |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Time to treatment failure after transplantation
Periodo de tiempo: Measured until 3 years after kidney transplantation
|
Treatment failure is a composite endpoint of biopsy-proven acute rejection, graft failure (defined as initiation of renal dialysis or pre-emptive re-transplantation), or death (from any cause) |
Measured until 3 years after kidney transplantation
|
|
Incidence rate, severity and time to clinically-confirmed biopsy-proven acute rejection
Periodo de tiempo: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Clinically-confirmed biopsy-proven acute rejection requires both a clinical diagnosis of rejection by an investigator and a histopathological diagnosis of rejection in a for-cause biopsy. Subclinical rejection diagnosed in a protocol biopsy is therefore excluded from this definition. |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Incidence rate of graft failure
Periodo de tiempo: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Graft failure is defined as initiation of renal dialysis or pre-emptive re-transplantation |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Mortality rate
Periodo de tiempo: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Mortality rate measures death from any cause |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Graft function measured by eGFR (estimated glomerular filtration rate)
Periodo de tiempo: 4 days, 14 days, 28 days, 12 weeks and 1, 2, 3 years after kidney transplantation
|
eGFR calculated according to the CKD-EPI formula |
4 days, 14 days, 28 days, 12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Incidence rate of delayed graft function
Periodo de tiempo: Measurable within the first 2 weeks after kidney transplantation
|
Delayed graft function is defined as the need for more than one episode of dialysis after transplantation |
Measurable within the first 2 weeks after kidney transplantation
|
|
Incidence rate of primary non-function of the renal allograft
Periodo de tiempo: Measurable within the first 12 weeks after kidney transplantation
|
Primary non-function is defined as the necessity for ongoing chronic dialysis |
Measurable within the first 12 weeks after kidney transplantation
|
|
Incidence of hepatotoxicity
Periodo de tiempo: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Hepatotoxicity is defined as GPT or GOT levels ≥ 2.5 x upper limit of normal range |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Incidence of de novo tremor
Periodo de tiempo: 12 weeks and 3 years after kidney transplantation
|
Incidence and severity of tremor based on medical assessment by the investigator |
12 weeks and 3 years after kidney transplantation
|
|
Incidence of new onset diabetes mellitus after transplantation (NODAT)
Periodo de tiempo: 12 weeks and 1, 2, 3 years after kidney transplantation
|
NODAT is defined as HbA1c ≥ 6.5% or 47.5 mmol/mol or fasting plasma glucose ≥ 126 mg/dl on two separate occasions |
12 weeks and 1, 2, 3 years after kidney transplantation
|
|
Patient-reported health-related quality-of-life measured using the Kidney Transplant Questionnaire-34 (KTQ-34)
Periodo de tiempo: 12 weeks and 3 years after kidney transplantation
|
The KTQ-34 is a renal transplantation-specific instrument that measures quality-of-life in five dimensions. It is a self-administered questionnaire that is completed in writing by the trial patients. |
12 weeks and 3 years after kidney transplantation
|
|
Dose of mycophenolate
Periodo de tiempo: 12 weeks and 1, 2, 3 years after kidney transplantation
|
Including both mycophenolate mofetil and mycophenolic acid |
12 weeks and 1, 2, 3 years after kidney transplantation
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Bernhard Banas, MD, University Hospital Regensburg
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- TaC:Drop
- 2023-503531-18-00 (Otro identificador: EUCT Number)
- 2023 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .